nach oben

Current Rheumatology Reports

Erschienen in:

01.07.2013 | PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Current Perspectives on Ophthalmic Manifestations of Childhood Rheumatic Diseases

verfasst von: Neal V. Palejwala, Steven Yeh, Sheila T. Angeles-Han

Erschienen in: Current Rheumatology Reports | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory eye diseases are an important manifestation of many pediatric rheumatologic conditions. Early screening and diagnosis are imperative as these illnesses can not only result in significant visual morbidity but are also an indicator of systemic inflammation. Time to presentation of ocular inflammation varies significantly and can range from many years prior to the onset of systemic symptoms to well after the diagnosis of the rheumatologic disorder. Due to this variability in presentation, careful monitoring by an ophthalmologist is vital to preventing ocular complications and preserving vision. Both local and systemic immunosuppressive medications have been effective in the management of ocular disease. In this review, we will focus on the known ophthalmologic manifestations of common pediatric rheumatologic diseases and discuss recent advances in therapeutic considerations for these conditions.

Reiff A. Ocular complications of childhood rheumatic diseases: Nonuveitic inflammatory eye diseases. Current Rheumatology Reports. 2009;11:226–32.PubMedCrossRef

Cunningham Jr ET. Uveitis in children. Ocul Immunol Inflamm. 2000;8:251–61.PubMedCrossRef

Zierhut M, Michels H, Stubiger N, et al. Uveitis in children. Int Ophthalmol Clin. 2005;45:135–56.PubMedCrossRef

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.PubMedCrossRef

Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed

Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2003;14:395–8.PubMedCrossRef

Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-term follow-up study. Arthritis & Rheumatism. 2007;56(2):647–57.CrossRef

Oren B, Sehgal A, Simon JW, et al. The prevalence of uveitis in juvenile rheumatoid arthritis. J AAPOS. 2001;5:2–4.PubMedCrossRef

Aggarwal A, Misra R. Juvenile chronic arthritis in India: is it different from that seen in Western countries? Rhumatol Int. 1994;14:53–6.CrossRef

10.

• Qian Y, Acharya NR. Juvenile idiopathic arthritis-associated uveitis. Current Opinion in Ophthalmology. 2010;21:468–72. This article nicely summarizes the recent literature about JIA-uveitis.PubMedCrossRef

11.

Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104:236–44.PubMedCrossRef

12.

de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87:879–84.PubMedCrossRef

13.

Thorne JE, Woreta F, Kedhar SR, et al. Juvenile idiopathic arthritis-associated uveitis: Incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840–46.PubMedCrossRef

14.

Hoeve M, Ayuso VK, Schalij-Delfos NE, et al. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Br J Ophthalmol. 2012;96:852–56.PubMedCrossRef

15.

Sabri K, Saurenmann RK, Silverman ED. Course, complications, and outcome of juvenile arthritis-related uveitis. Journal of AAPOS. 2008;12(6):539–45.PubMedCrossRef

16.

Marvillet I, Terrada C, Quartier P, et al. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine. 2009;76:383–88.PubMedCrossRef

17.

Gregory AC, Kempen JH, Daniel EB. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: The systemic immunosuppressive therapy for eye diseases study. Ophthalmology. 2013;120:186–92.PubMedCrossRef

18.

Woreta F, Thorne JE, Jabs DA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647–55.PubMedCrossRef

19.

Section on Rheumatology and Section on Ophthalmology. Guidelines for ophthalmologic examination in children with juvenile rheumatoid arthritis. Pediatrics. 1993;92(2):295–6.

20.

Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children age 8–18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis and Rheumatism. 2011;63(9):1254–61.CrossRef

21.

Paroli MP, Spinucci G, Fabiani C, Pivetti-Pezzi P. Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence tomography study. Ocul Immunol Inflamm. 2010;18(1):54–9.PubMedCrossRef

22.

Edelsten C, Lee V, Bentley CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:51–6.PubMedCrossRef

23.

Ayuso VK, ten Cate HAT, van der Does P, et al. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2010;149:994–9.CrossRef

24.

Cabral DA, Petty RE, Malleson PN, et al.: Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 21:2370–2375

25.

Hofer M, Southwood TR. Classification of childhood arthritis. Best Prac Res Clin Rheumatol. 2002;16:379–96.

26.

Horneff G, Burgos-Vargas R. Juvenile idiopathic arthritis. Sub-group characteristics and comparisons between rheumatoid arthritis–like subgroups and ankylosing spondylitis–like subgroups. Clin Exp Rheumatol. 2009;27:S131–8.PubMed

27.

• Scofield RH, Sestak AL. Juvenile spondyloarthropathies. Curr Rheumatol Rep. 2012;14:395–401. This article summarizes the current literature on juvenile spondyloarthropathies.PubMedCrossRef

28.

Stoll ML, Bhore R, Dempsy-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: Risk factors for sacroiliitis. J Rheumatol. 2010;37(11):2402–8.PubMedCrossRef

29.

Ozgocmen S, Ardicoglu O, Kamanli A. Pattern of Disease Onset, Diagnostic Delay, and Clinical Features in Juvenile Onset and Adult Onset Ankylosing Spondylitis. J Rheumatol. 2009;36:2830–3.PubMedCrossRef

30.

Liao CH, Huang JL. Juvenile ankylosing spondilitis with uveitis. Asian Pacific Journal of Allergy and Immunology. 2003;21:69–71.PubMed

31.

Silva-Ramírez B, Vargas-Alarcón G, Granados J, Burgos-Vargas R. HLA antigens and juvenile onset spondyloarthritides: negative association with non-B27 alleles. Clin Exp Rheumatol. 2005;23(5):721–3.PubMed

32.

Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127–37.PubMedCrossRef

33.

Kollnberger S, Bird LA, Roddis M, et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol. 2004;173:1699–710.PubMed

34.

Mear JP, Schreiber KL, Münz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol. 1999;163:6665–70.PubMed

35.

Cokington CD, Han DP. Bilateral nongranulomatous uveitis and a post-streptococcal syndrome. Am J Ophthalmol. 1991;112(5):595–6.

36.

Rehman S, Anand S, Reddy A, et al. Post streptococcal syndrome uveitis: a descriptive case series and literature review. Ophthalmology. 2006;113(4):701–6.CrossRef

37.

Nataneli N, Aguilera ZP, Rosenbaum PS, et al. Poststreptococcal keratouveitis associated with group C streptococcus pharyngitis. Clinical Ophthalmology. 2011;5:1257–59.PubMed

38.

Ansell B. Reactive arthritis/Reiter’s syndrome in children. Clin Exp Rheumatol. 1994;12:581–82.PubMed

39.

Keat A. Reiter’s syndrome and reactive arthritis in perspective. N Engl J Med. 1988;309:1606–15.CrossRef

40.

Manimegalai N, Rajamurugan A, Rajendran P, et al. Childhood reactive arthritis. J Clin Rheumatol. 2008;14(5):292–93.PubMedCrossRef

41.

Singsen B, Bernstein B, Koster-King K, Glovsky M, Hansen V. Reiter's syndrome in childhood. Arthritis Rheum. 1977;20(Suppl):402–7.PubMed

42.

Tinley C, Van Zyl L, Grötte R. Poststreptococcal syndrome uveitis in South African children. Br J Ophthalmol. 2012;96(1):87–9.PubMedCrossRef

43.

Kiss S, Letko E, Qamruddin S, Baltatzis S, Foster S. Ocular Manifestions of Reiter’s Syndrome. Ophthalmology. 2003;110:1764–69.PubMedCrossRef

44.

Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009 Aug;116(8):1544–51.

45.

Nikkhah H, Ramezani A, Ahmadieh H, et al. Childhood pars planitis; clinical features and outcomes. J Ophthalmic Vis Res. 2011;6(4):249–54.PubMed

46.

Donaldson MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: A 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007;144:812–7.PubMedCrossRef

47.

Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA association. Ophthalmology. 1999;106:594–9.PubMedCrossRef

48.

Arellans-Garcia L, Navarro-Lopez LP, Recillas- Gispert C. Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome. Ocul Immunol Inflamm. 2003;11:53–60.CrossRef

49.

Romero R, Peralta J, Sendagorta E, Abelairas J. Pars planitis in children: epidemiologic, clinical and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44:288–93.PubMed

50.

Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clinical and Experimental Ophthalmology. 2001;29:81–4.PubMedCrossRef

51.

Cimaz R, Ansell BM. Sarcoidosis in the pediatric age. Clin Exp Rheumatol. 2002;20:231–7.PubMed

52.

Choi DE, Birnbaum AD, Oh F, Tessler HH, Goldstein DA. Pediatric uveitis secondary to probable, presumed, and biopsy-proven sarcoidosis. J Pediatr Ophthalmol Strabismus. 2011;48(3):157–62.PubMedCrossRef

53.

Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004;93:30–6.PubMedCrossRef

54.

Shetty AK, Gedalia A. Childhood sarcoidosis: a rare but fascinating disorder. Pediatr Rheumatol Online. 2008;6:6.CrossRef

55.

Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila). 1998;37:707–17.CrossRef

56.

Kataria S, Trevathan GE, Holland JE, Kataria YP. Ocular presentation of sarcoidosis in children. Clin Pediatr (Phila). 1983;22:793–7.CrossRef

57.

Pattishall EN, Kendig Jr EL. Sarcoidosis in children. Pediatr Pulmonol. 1996;22:195–203.PubMedCrossRef

58.

James DG, Neville E, Langley DA. Ocular sarcoidosis. Trans Ophthalmol Soc UK. 1976;96:133–9.PubMed

59.

Khalatbari D, Stinnett S, McCallum RM, Jaffe GJ. Demographic-related variations in posterior segment ocular sarcoidosis. Ophthalmology. 2004;111:357–62.PubMedCrossRef

60.

Yanardag H, Pamuk ON. Lacrimal gland involvement in sarcoidosis: the clinical features of 9 patients. Swiss Med Wkly. 2003;133:388–91.PubMed

61.

Habibi S, Saleem MA, Ramanan AV. Juvenile systemic lupus erythematosus: review of clinical features and management. Indian Pediatrics. 2011;48:879–86.PubMedCrossRef

62.

Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42:1354–60.PubMedCrossRef

63.

Guiterrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the systemic lupus international collaborating clinics/American college of Rheumatology damage index based on the on analysis of 1,015 patients with juvenile-onset systemic lupus erthematosus. Arthritis & Rheumatism. 2006;54(9):2989–96.CrossRef

64.

Brunner HI, Gladman DD. Ibañez D, Urowitz MD, Silverman ED: Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556–62.PubMedCrossRef

65.

Font J, Cervera R, Espinosa G et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults.

66.

Almeida RT, Aikawa NE, Sallum AME, et al. Irreversible blindness in juvenile systemic lupus erythematosus. Lupus. 2011;20:95–7.PubMedCrossRef

67.

Avcin T, Silverman ED. Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16:627–33.PubMedCrossRef

68.

Montehermoso A, Cervera R, Font J, et al. Association of antiphopholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Sem Arth Rheum. 1999;28(5):326–32.CrossRef

69.

Hannouche D et al. Systemic lupus erythematosus with choroidopathy and serous retinal detachment. Int Ophthalmol. 1995;19:125–27.PubMedCrossRef

70.

Schwartz M, Roberts J. Membranous and vascular choroidopathy: two patterns of immune deposits in systemic lupus erythematosus. Clin Immunol Immunopathol. 1983;29:369–80.PubMedCrossRef

71.

Matsuo T et al. Multifocal pigment epithelial damages with serous retinal detachment in systemic lupus erythematosus. Ophthalmologica. 1987;195:97–102.PubMedCrossRef

72.

• Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: A review of the literature. Autoimmune Dis. 2012. This review summarizes the ocular complications that are commonly seen in systemic lupus erythematosus.

73.

Soylu M, Ozdemir G, Anli A. Pediatric uveitis in Southern Turkey. Ocul Immunol Inflamm. 1997;5:197–202.PubMedCrossRef

74.

Mochizuki M, Akduman L, Nussenblatt RB. Behcet’s disease. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. St Louis: Mosby; 1996. p. 663–75.

75.

Fujikawa S, Suesmitus T. Behcet disease in children: A nationwide retrospective survery in Japan. Acta Paediatrica Japonica. 1997;39:285–89.PubMedCrossRef

76.

Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behcet disease: A descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114–19.PubMedCrossRef

77.

Koné-Paut I, Yurdakul S, Bahabri SA, et al. Clinical features of Behcet’s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132:721–5.PubMedCrossRef

78.

Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S. Low prevalence of juvenile-onset Behçet’s disease with uveitis in East/South Asian people. Br J Ophthalmol. 2009;93(11):1428–30.PubMedCrossRef

79.

Atmaca L, Boyvat A, Yalcindag N, et al. Behcet disease in children. Ocular Immunology & Inflammation. 2011;19(2):103–7.CrossRef

80.

Colvard DM, Robertson DM, O’Duffy JD. The ocular manifestations of Behcet’s disease. Arch Ophthalmol. 1977;95:1813–15.PubMedCrossRef

81.

Citirik M, Berker N, Songur MS. Ocular findings in childhood-onset Behcet disease. J AAPOS. 2009;13:291–95.

82.

Pivetti-Pezzi P, Accorinti M, Abdulaziz MA, La Cava M, Torella M, Riso D. Behcet’s disease in children. Jpn J Ophthalmol. 1995;39:309–14.PubMed

83.

Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric Behcet disease in the American Midwest. Am J Ophthalmol. 2008;146:819–27.PubMedCrossRef

84.

Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas H, Urgancioglu M. Uveitis in Behcet disease: An analysis of 880 patients. Am J Ophthalmol. 2004;138:373–80.PubMedCrossRef

85.

Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011;63:863–4.PubMedCrossRef

86.

Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60(11):3413–24.PubMedCrossRef

87.

Vanoni F, Bettinelli A, Keller F, et al. Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol. 2010;25:205–12.PubMedCrossRef

88.

Schmidt J, Pulido JS, Matteson EL. Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Ophthalmol. 2011;22:489–95.PubMedCrossRef

89.

Jiang B, Zhao YY, Wei SH. Granulomatosis with polyangiitis: The relationship between ocular and nasal disease. Ocul Immunol Inflamm. 2012 [Epub].

90.

Vischio JA, McCrary CT. Orbital Wegener's granulomatosis: a case report and review of the literature. Clin Rheumatol. 2008;27(10):1333–6.PubMedCrossRef

91.

Shiboski SC, Shiboski CH, Criswell LA et al. American college of rheumatology classification criteria for Sjogren’s syndrome: A data-driven expert consensus approach in the Sjogren’s international collaborative clinical alliance cohort. 2012; 64(4): 475–87

92.

Hernández-Molina G, Avila-Casado C, Cárdenas-Velázquez F, et al. Similarities and differences between primary and secondary Sjögren's syndrome. J Rheumatol. 2010;37(4):800–8.PubMedCrossRef

93.

Civilibal M, Canpolat N, Yurt A. A child with primary Sjogren Syndrome and a review of the literature. Clinical Pediatrics. 2007;46(8):738–42.PubMedCrossRef

94.

Cimaz R, Casadei A, Rose C, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661–65.PubMedCrossRef

95.

Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjogren’s syndrome in children and adolescents: are proposed diagnostic criteria applicable. J Rheumatol. 2005;32:2225–32.PubMed

96.

Bartunkova J, Sediva A, Vencovsky J, Tesar V. Primary Sjogren’s syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. 1999;17:381–6.PubMed

97.

Stiller M, Golder W, Döring E, et al. Primary and secondary Sjögren's syndrome in children–a comparative study. Clin Oral Investig. 2000;4(3):176–82.PubMedCrossRef

98.

Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. J Epidemiol. 2010;20(4):302–07.PubMedCrossRef

99.

Lin YT, Manlhiot C, Ching JC, et al. Repeated systemic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int. 2010;52:699–706.PubMedCrossRef

100.

Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation. 2004;110:2747–71.PubMedCrossRef

101.

Burke MJ, Rennebohm RM. Eye involvement in Kawasaki disease. J Pediatr Ophthalmol Strabismus. 1981;18:7–11.PubMed

102.

Kadyan A, Choi J, Headon MP. Disciform keratitis and optic disc swelling in Kawasaki disease: an unusual presentation. Eye. 2006;20(8):976–7.PubMedCrossRef

103.

Burns JC, Joffe L, Sargent RA, Glode MP. Anterior uveitis associated with Kawasaki syndrome. Pediatr Infect Dis. 1985;4:258–61.PubMedCrossRef

104.

Rennebohm RM, Burke MJ, Crowe W, et al. Anterior uveitis in Kawasaki’s disease. Am J Ophthalmol. 1981;91(4):535–37.PubMed

105.

Burke MJ, Rennebohm RM. Eye involvement in Kawasaki disease. J Pediatr Ophthalmol Strabismus. 1981;18(5):7–11.PubMed

106.

Farvardin M, Kashef S, Aleyasin S, et al. Sudden unilateral blindness in a girl with Kawasaki disease. J Pediatr Ophthalmol Strabismus. 2007;44:303–04.PubMed

107.

Grouteau E, Dubuisson C, Brochard K, et al. Severe global inflammatory involvement of ocular segments and optic disc swelling in a 12 year-old girl with Kawasaki disease. Eur J Ophthalmol. 2011;21:112–14.PubMedCrossRef

108.

Garweg JG, Suter C, Aebi-Ochsner. Macular oedema in Kawasaki syndrome. Gaefes Arch Clin Exp Ophthalmol. 2012;250:1101–04.CrossRef

109.

Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55:603–13.PubMedCrossRef

110.

• Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile-idiopathic arthritis uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–41. This retrospective cohort study showed that >3 drops of topical corticosteroids was associated with a significantly increased risk of cataract formation.PubMedCrossRef

111.

Romero R, Peralta J, Sendagorta E, Abelairas J. Pars planitis in children: epidemiologic, clinical and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44(5):288–93.PubMed

112.

Beukelman T, Ringold S, Davis TE, et al. CARRA Registry Investigators. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39(9):1867–74.PubMedCrossRef

113.

Schatz CS, Uzel JL, Leininger L, et al. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis. J Pediatr Ophthalmol Strabismus. 2007;44(1):28–34.PubMed

114.

Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252–7.PubMedCrossRef

115.

Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(8):982–9.PubMedCrossRef

116.

Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146–50.PubMed

117.

Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860–4.PubMedCrossRef

118.

• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–9. Infliximab and adalimumab appear to be effective and safe for the treatment of refractory uveitis.PubMedCrossRef

119.

Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339–44.PubMedCrossRef

120.

Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44(6):1411–5.PubMedCrossRef

121.

Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(8):1008–11.PubMedCrossRef

122.

Taban M, Dupps WJ, Mandell B, et al. Etanercept (enbrel)-associated in- flammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14:145–50.PubMedCrossRef

123.

Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol. 2008;35(9):1897–8.PubMed

124.

William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231–3.PubMedCrossRef

125.

Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009;148(5):696–703.PubMedCrossRef

126.

Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: Indications, toxicities, and guidelines. J Am Acad Dermatol. 1993;28:764–70.PubMedCrossRef

127.

Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.PubMedCrossRef

128.

American College of Rheumatology: Screening for hydroxychloroquine retinopathy. Available at: https://www.rheumatology.org/practice/clinical/position/hydroxyp2.pdf. Accessed February 2013.

129.

• Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children ages 8–18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). 2011;63(9):1254–61. This study provides evidence of the validity and reliability of the EYE-Q in the measurement of VRQOL.CrossRef

130.

Angeles-Han ST, Griffin KW, Lehman TJ, et al. The importance of visual function in the quality of life of children with uveitis. J AAPOS. Mar 15 2010.

Titel: Current Perspectives on Ophthalmic Manifestations of Childhood Rheumatic Diseases
verfasst von: Neal V. Palejwala
Steven Yeh
Sheila T. Angeles-Han
Publikationsdatum: 01.07.2013
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 7/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-013-0341-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Current Perspectives on Ophthalmic Manifestations of Childhood Rheumatic Diseases

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies

Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

Update on Oxalate Crystal Disease

Tocilizumab in Pediatric Rheumatology: The Clinical Experience

Manipulative Therapy (Feldenkrais, Massage, Chiropractic Manipulation) for Neck Pain

Osteoimmunology and Bone Homeostasis: Relevance to Spondyloarthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin